Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
7(64%)
Results Posted
100%(3 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_2
7
64%
Ph phase_4
1
9%
Ph phase_1
2
18%

Phase Distribution

2

Early Stage

7

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
7(70.0%)
Phase 4Post-market surveillance
1(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

11

all time

Status Distribution
Active(7)
Completed(3)
Terminated(1)

Detailed Status

Recruiting5
Completed3
Active, not recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
7
Success Rate
75.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 27 (70.0%)
Phase 41 (10.0%)

Trials by Status

completed327%
terminated19%
active_not_recruiting218%
recruiting545%

Recent Activity

7 active trials
Showing 5 of 11
recruitingphase_4

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

NCT07573943
completedphase_2

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

NCT04856085
completedphase_1

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

NCT05612581
recruitingphase_2

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

NCT06425341
recruitingphase_2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

NCT05771402
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07573943Phase 4

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

Recruiting
NCT04856085Phase 2

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Completed
NCT05612581Phase 1

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

Completed
NCT06425341Phase 2

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

Recruiting
NCT05771402Phase 2

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

Recruiting
NCT05970289Phase 2

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

Active Not Recruiting
NCT06650852Phase 2

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

Recruiting
NCT06491563Phase 2

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

Active Not Recruiting
NCT06696664

Exploring the Genome-wide Association Study of the Population With Clinical Cure Advantage in the Treatment of Chronic Hepatitis B With Long-acting Interferon

Recruiting
NCT04781647Phase 2

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

Terminated
NCT02328755Phase 1

Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11